• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Ambu

63.35 DKK

+0.40 %

Less than 1K followers

AMBU B

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.40 %
+1.44 %
-11.89 %
-28.01 %
-27.06 %
-34.72 %
-41.75 %
-73.03 %
+6,481.82 %

Ambu is active in medical technology. The company develops and markets diagnostic equipment for actors in healthcare. The largest activity is found in the development of solutions for endoscopy, gastroscopy and patient monitoring. Operations are held on a global level with the largest presence in Europe and North America. Ambu was founded in 1937 and is headquartered in Ballerup, Denmark.

Read more
Market cap
17.06B DKK
Turnover
49.4M DKK
Revenue
6.04B
EBIT %
12.99 %
P/E
27.66
Dividend yield-%
0.65 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
Today, the Q4 interim report for FY2019/20 was released. The endoscope business grew by 81% and accounted for 48% of the company’s revenue during the fiscal year. Growth is expected to continue at a good level. In terms of units, 1.085 million endoscopes were sold, and sales of 1...
11/11/2020, 9:39 AM
by Mikko Kiesiläinen
4
However, even this company made its biggest profit ever in 2025 (it probably increased by about 2.5 times from 2024), and revenue is growing very predictably (year after year). I think the decline experienced in the stock is just a correction of the high valuation of previous years...
3/20/2026, 7:21 AM
3
Since the thread has been dead for years, I dare to ask silly questions even with shaky knowledge. Has anyone more knowledgeable followed the endoscopy market in recent years? What does the competitive situation look like now that healthcare has returned to normal times? When I looked...
3/19/2026, 1:11 PM
by Zoltan
3
The markets didn’t like it; down nearly -5% today. Revenue growth slowed and operating profit decreased—pretty sluggish figures. I considered buying several times, but luckily I didn’t hit the buy button. Their performance isn’t convincing when, according to them, there should be...
5/6/2026, 2:19 PM
by Zoltan
2
Salkunrakentaja has an article about this: SalkunRakentaja – 21 Aug 21 Tanskalainen Ambu kasvaa vauhdilla uusien tuotteiden siivittämänä Sairaaloiden ja pelastuslaitosten laitevalmistaja Ambu saa Handelsbankenilta ostosuosituksen. Yhtiöön kohdistuu kovat kasvuodotukset. The article...
8/22/2021, 6:04 AM
by Ruudolf
1
Q3 was released a few days ago: Investor Relations Still seems expensive. Growth has stumbled a bit this year. It would be interesting to know more precisely why, and whether the problems are temporary.
8/22/2021, 4:09 AM
by Taavetti
1
Ambu’s results will be out tomorrow. The valuation level is certainly dizzying. With the numbers for the 2021E financial year ending in September, the EV/EBITDA is 89.4x. If there is a disappointment tomorrow, the drop could be significant.
1/26/2021, 8:37 AM
by Mikko Kiesiläinen
1
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8
2026

Interim report Q3'26

5.11
2026

Annual report '26

2.12
2026

General meeting '26

Regulatory press release11 hours ago

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
Regulatory press release6/9/2026, 7:35 AM

REPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Ambu
Regulatory press release6/8/2026, 9:36 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/4/2026, 2:57 PM

REPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Ambu
HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk
Video6/3/2026, 7:29 AM by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk

I dagens Morgenbørs kigger vi ind i overvejende negative markeder, hvor USA-Iran konflikten igen synes at skygge for AI-euforien. Fokus herhjemme på Genmab og Novo Nordisk.

Novo NordiskGenmabDanish Aerospace and Defence CompanyHafniaFLSmidth & Co.BioMar GroupSwiss Properties InvestDSVRockwoolAmbuBavarian Nordic
Regulatory press release6/1/2026, 8:46 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
Regulatory press release5/26/2026, 8:01 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
Regulatory press release5/18/2026, 8:41 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
Regulatory press release5/11/2026, 3:20 PM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
Regulatory press release5/7/2026, 11:10 AM

REPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Ambu
HCA Morgenbørs 06/05 - Stor dansk regnskabsdag
Video5/6/2026, 7:28 AM by
Victor Skriver

HCA Morgenbørs 06/05 - Stor dansk regnskabsdag

I dagens Morgenbørs ser vi ind i et positivt futuresmarked med tro på en mulig fredsaftale i Mellemøsten. Herhjemme er der stor regnskabsdag med regnskaber fra bl.a. Novo Nordisk, Vestas, Pandora, Demant, Ørsted og Ambu.

Novo NordiskVestas Wind SystemsPandoraDemantAmbuØrstedD/S NordenGubra
Regulatory press release5/6/2026, 5:10 AM

AMBU INITIATES NEW SHARE BUYBACK PROGRAM

Ambu
Regulatory press release5/6/2026, 5:00 AM

INTERIM REPORT FOR Q2 and H1 2025/26

Ambu
HCA Morgenbørs 08/04 - Udsigt til festdag på aktiemarkedet efter våbenhvile i Mellemøsten
Video4/8/2026, 7:27 AM by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 08/04 - Udsigt til festdag på aktiemarkedet efter våbenhvile i Mellemøsten

I dagens Morgenbørs ser vi ind i meget positive aktiemarkeder med plusser på 3-6% ovenpå udsigten til våbenhvile i Mellemøsten. Herhjemme fokus på bl.a. Vestas, Novo Nordisk og NTG.

FLSmidth & Co.A.P. Møller - MærskNTG Nordic Transport GroupAmbuINVISIOTormHafniaD/S NordenTrifork GroupVestas Wind SystemsJyske BankRockwoolCarlsberg
Regulatory press release2/12/2026, 8:37 AM

AMBU’S SHARE BUYBACK PROGRAM HAS BEEN FINALIZED

Ambu
Regulatory press release2/9/2026, 7:56 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu
HCA Morgenbørs 04/02 - Danske regnskaber i fokus
Video2/4/2026, 8:28 AM by
Victor Skriver, Rasmus Køjborg

HCA Morgenbørs 04/02 - Danske regnskaber i fokus

I dagens Morgenbørs ser vi ind i marginalt positive futures-markeder efter kursfaldene i går. Herhjemme i høj grad fokus på Novo Nordisk og andre større regnskabsaktuelle selskaber som DSV, Carlsberg, Lundbeck og NORDEN.

Novo NordiskDSVCarlsbergRingkjøbing LandbobankD/S NordenLundbeckAmbuChemoMetec
Regulatory press release2/4/2026, 6:04 AM

INTERIM REPORT FOR Q1 2025/26

Ambu
Regulatory press release2/3/2026, 8:43 AM

LAUNCH OF LONG-TERM INCENTIVE PLAN FOR EXECUTIVE MANAGEMENT AND KEY EMPLOYEES

Ambu
Regulatory press release2/2/2026, 7:44 AM

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

Ambu